TMT (India) Ltd. (BSE: TMTIND-B1.BO) Stock Competitors & Peer Comparison
See TMTIND-B1.BO's competitors and their performance on the BSE and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for TMTIND-B1.BO and its BSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TMTIND-B1.BO | ₹8.87 | +4.97% | 43.9M | -49.28 | -₹0.18 | N/A |
| JBCHEPHARM.NS | ₹2,416.10 | +0.30% | 387.9B | 52.07 | ₹46.40 | +0.91% |
| JBCHEPHARM.BO | ₹2,412.25 | -3.70% | 387.3B | 50.89 | ₹47.40 | +0.91% |
| WOCKPHARMA.NS | ₹2,086.10 | +0.67% | 339B | 159.12 | ₹13.11 | N/A |
| WOCKPHARMA.BO | ₹2,086.95 | +0.78% | 338.9B | 159.19 | ₹13.11 | N/A |
| MEDPLUS.BO | ₹659.50 | +0.83% | 79.3B | 35.08 | ₹18.80 | N/A |
| MEDPLUS.NS | ₹659.65 | +0.86% | 79.2B | 35.70 | ₹18.48 | N/A |
| SUPRIYA.NS | ₹906.30 | +0.63% | 73.2B | 35.00 | ₹26.00 | +0.11% |
| SUPRIYA.BO | ₹905.50 | +0.75% | 72.9B | 36.70 | ₹24.67 | +0.11% |
| SANOFI.BO | ₹3,088.00 | -0.03% | 71.1B | 20.34 | ₹151.80 | +3.98% |
Stock Comparison
J. B. Chemicals & Pharmaceuticals Limited (NSE: JBCHEPHARM.NS)
TMTIND-B1.BO vs JBCHEPHARM.NS Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, JBCHEPHARM.NS has a market cap of 387.9B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while JBCHEPHARM.NS trades at ₹2,416.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas JBCHEPHARM.NS's P/E ratio is 52.07. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to JBCHEPHARM.NS's ROE of +0.19%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to JBCHEPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check JBCHEPHARM.NS's competition here
J. B. Chemicals & Pharmaceuticals Limited (BSE: JBCHEPHARM.BO)
TMTIND-B1.BO vs JBCHEPHARM.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, JBCHEPHARM.BO has a market cap of 387.3B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while JBCHEPHARM.BO trades at ₹2,412.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas JBCHEPHARM.BO's P/E ratio is 50.89. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to JBCHEPHARM.BO's ROE of +0.19%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to JBCHEPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check JBCHEPHARM.BO's competition here
Wockhardt Limited (NSE: WOCKPHARMA.NS)
TMTIND-B1.BO vs WOCKPHARMA.NS Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, WOCKPHARMA.NS has a market cap of 339B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while WOCKPHARMA.NS trades at ₹2,086.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas WOCKPHARMA.NS's P/E ratio is 159.12. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to WOCKPHARMA.NS's ROE of +0.08%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to WOCKPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check WOCKPHARMA.NS's competition here
Wockhardt Limited (BSE: WOCKPHARMA.BO)
TMTIND-B1.BO vs WOCKPHARMA.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, WOCKPHARMA.BO has a market cap of 338.9B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while WOCKPHARMA.BO trades at ₹2,086.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas WOCKPHARMA.BO's P/E ratio is 159.19. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to WOCKPHARMA.BO's ROE of +0.08%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to WOCKPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check WOCKPHARMA.BO's competition here
MedPlus Health Services Limited (BSE: MEDPLUS.BO)
TMTIND-B1.BO vs MEDPLUS.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, MEDPLUS.BO has a market cap of 79.3B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while MEDPLUS.BO trades at ₹659.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas MEDPLUS.BO's P/E ratio is 35.08. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to MEDPLUS.BO's ROE of +0.11%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to MEDPLUS.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check MEDPLUS.BO's competition here
MedPlus Health Services Limited (NSE: MEDPLUS.NS)
TMTIND-B1.BO vs MEDPLUS.NS Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, MEDPLUS.NS has a market cap of 79.2B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while MEDPLUS.NS trades at ₹659.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas MEDPLUS.NS's P/E ratio is 35.70. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to MEDPLUS.NS's ROE of +0.11%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to MEDPLUS.NS. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check MEDPLUS.NS's competition here
Supriya Lifescience Limited (NSE: SUPRIYA.NS)
TMTIND-B1.BO vs SUPRIYA.NS Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, SUPRIYA.NS has a market cap of 73.2B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while SUPRIYA.NS trades at ₹906.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas SUPRIYA.NS's P/E ratio is 35.00. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to SUPRIYA.NS's ROE of +0.17%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to SUPRIYA.NS. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check SUPRIYA.NS's competition here
Supriya Lifescience Ltd (BSE: SUPRIYA.BO)
TMTIND-B1.BO vs SUPRIYA.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, SUPRIYA.BO has a market cap of 72.9B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while SUPRIYA.BO trades at ₹905.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas SUPRIYA.BO's P/E ratio is 36.70. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to SUPRIYA.BO's ROE of +0.17%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to SUPRIYA.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check SUPRIYA.BO's competition here
Sanofi India Limited (BSE: SANOFI.BO)
TMTIND-B1.BO vs SANOFI.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, SANOFI.BO has a market cap of 71.1B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while SANOFI.BO trades at ₹3,088.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas SANOFI.BO's P/E ratio is 20.34. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to SANOFI.BO's ROE of +0.40%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to SANOFI.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check SANOFI.BO's competition here
Sanofi India Limited (NSE: SANOFI.NS)
TMTIND-B1.BO vs SANOFI.NS Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, SANOFI.NS has a market cap of 71.1B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while SANOFI.NS trades at ₹3,087.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas SANOFI.NS's P/E ratio is 20.34. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to SANOFI.NS's ROE of +0.40%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to SANOFI.NS. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check SANOFI.NS's competition here
Kwality Pharmaceuticals Limited (BSE: KPL.BO)
TMTIND-B1.BO vs KPL.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, KPL.BO has a market cap of 36B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while KPL.BO trades at ₹3,469.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas KPL.BO's P/E ratio is 86.71. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to KPL.BO's ROE of +0.26%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to KPL.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check KPL.BO's competition here
Hikal Limited (NSE: HIKAL.NS)
TMTIND-B1.BO vs HIKAL.NS Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, HIKAL.NS has a market cap of 28.1B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while HIKAL.NS trades at ₹226.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas HIKAL.NS's P/E ratio is 16.28. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to HIKAL.NS's ROE of -0.03%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to HIKAL.NS. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check HIKAL.NS's competition here
Hikal Limited (BSE: HIKAL.BO)
TMTIND-B1.BO vs HIKAL.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, HIKAL.BO has a market cap of 27.8B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while HIKAL.BO trades at ₹226.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas HIKAL.BO's P/E ratio is 196.61. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to HIKAL.BO's ROE of -0.03%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to HIKAL.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check HIKAL.BO's competition here
Shukra Pharmaceuticals Limited (BSE: SHUKRAPHAR.BO)
TMTIND-B1.BO vs SHUKRAPHAR.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, SHUKRAPHAR.BO has a market cap of 24.5B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while SHUKRAPHAR.BO trades at ₹55.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas SHUKRAPHAR.BO's P/E ratio is 111.92. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to SHUKRAPHAR.BO's ROE of +0.44%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to SHUKRAPHAR.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check SHUKRAPHAR.BO's competition here
Fredun Pharmaceuticals Limited (BSE: FREDUN.BO)
TMTIND-B1.BO vs FREDUN.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, FREDUN.BO has a market cap of 21.6B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while FREDUN.BO trades at ₹1,305.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas FREDUN.BO's P/E ratio is 51.39. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to FREDUN.BO's ROE of +0.20%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to FREDUN.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check FREDUN.BO's competition here
Accent Microcell Limited (NSE: ACCENTMIC.NS)
TMTIND-B1.BO vs ACCENTMIC.NS Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, ACCENTMIC.NS has a market cap of 16.4B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while ACCENTMIC.NS trades at ₹681.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas ACCENTMIC.NS's P/E ratio is 36.55. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to ACCENTMIC.NS's ROE of N/A. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to ACCENTMIC.NS. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check ACCENTMIC.NS's competition here
Remus Pharmaceuticals Ltd. (NSE: REMUS.NS)
TMTIND-B1.BO vs REMUS.NS Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, REMUS.NS has a market cap of 11.5B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while REMUS.NS trades at ₹979.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas REMUS.NS's P/E ratio is 27.36. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to REMUS.NS's ROE of N/A. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to REMUS.NS. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check REMUS.NS's competition here
Vikram Thermo (India) Limited (BSE: VIKRAMTH.BO)
TMTIND-B1.BO vs VIKRAMTH.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, VIKRAMTH.BO has a market cap of 10.6B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while VIKRAMTH.BO trades at ₹337.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas VIKRAMTH.BO's P/E ratio is 42.31. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to VIKRAMTH.BO's ROE of +0.32%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to VIKRAMTH.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check VIKRAMTH.BO's competition here
One Global Service Provider Ltd. (BSE: ONEGLOBAL.BO)
TMTIND-B1.BO vs ONEGLOBAL.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, ONEGLOBAL.BO has a market cap of 10.6B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while ONEGLOBAL.BO trades at ₹540.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas ONEGLOBAL.BO's P/E ratio is 15.19. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to ONEGLOBAL.BO's ROE of +0.61%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to ONEGLOBAL.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check ONEGLOBAL.BO's competition here
Bharat Parenterals Limited (BSE: BPLPHARMA.BO)
TMTIND-B1.BO vs BPLPHARMA.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, BPLPHARMA.BO has a market cap of 10.4B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while BPLPHARMA.BO trades at ₹1,504.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas BPLPHARMA.BO's P/E ratio is -129.11. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to BPLPHARMA.BO's ROE of -0.05%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to BPLPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check BPLPHARMA.BO's competition here
Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO)
TMTIND-B1.BO vs SUDARSHAN.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, SUDARSHAN.BO has a market cap of 9.9B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while SUDARSHAN.BO trades at ₹39.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas SUDARSHAN.BO's P/E ratio is 40.90. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to SUDARSHAN.BO's ROE of +0.18%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to SUDARSHAN.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check SUDARSHAN.BO's competition here
Sastasundar Ventures Limited (NSE: SASTASUNDR.NS)
TMTIND-B1.BO vs SASTASUNDR.NS Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, SASTASUNDR.NS has a market cap of 9B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while SASTASUNDR.NS trades at ₹282.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas SASTASUNDR.NS's P/E ratio is 34.59. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to SASTASUNDR.NS's ROE of +0.00%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to SASTASUNDR.NS. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check SASTASUNDR.NS's competition here
Shree Ganesh Remedies Limited (BSE: SGRL.BO)
TMTIND-B1.BO vs SGRL.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, SGRL.BO has a market cap of 9B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while SGRL.BO trades at ₹698.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas SGRL.BO's P/E ratio is 53.96. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to SGRL.BO's ROE of +0.10%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to SGRL.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check SGRL.BO's competition here
Bafna Pharmaceuticals Limited (NSE: BAFNAPH.NS)
TMTIND-B1.BO vs BAFNAPH.NS Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, BAFNAPH.NS has a market cap of 7.5B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while BAFNAPH.NS trades at ₹317.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas BAFNAPH.NS's P/E ratio is 67.63. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to BAFNAPH.NS's ROE of +0.08%. Regarding short-term risk, TMTIND-B1.BO is similarly volatile compared to BAFNAPH.NS. This indicates similar risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check BAFNAPH.NS's competition here
Bafna Pharmaceuticals Ltd. (BSE: BAFNAPH.BO)
TMTIND-B1.BO vs BAFNAPH.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, BAFNAPH.BO has a market cap of 7.5B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while BAFNAPH.BO trades at ₹322.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas BAFNAPH.BO's P/E ratio is 68.76. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to BAFNAPH.BO's ROE of +0.08%. Regarding short-term risk, TMTIND-B1.BO is similarly volatile compared to BAFNAPH.BO. This indicates similar risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check BAFNAPH.BO's competition here
Praveg Ltd. (BSE: PRAVEG.BO)
TMTIND-B1.BO vs PRAVEG.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, PRAVEG.BO has a market cap of 6.5B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while PRAVEG.BO trades at ₹247.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas PRAVEG.BO's P/E ratio is 34.86. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to PRAVEG.BO's ROE of -0.04%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to PRAVEG.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check PRAVEG.BO's competition here
Albert David Limited (BSE: ALBERTDA.BO)
TMTIND-B1.BO vs ALBERTDA.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, ALBERTDA.BO has a market cap of 6.2B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while ALBERTDA.BO trades at ₹1,084.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas ALBERTDA.BO's P/E ratio is 32.30. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to ALBERTDA.BO's ROE of -0.01%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to ALBERTDA.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check ALBERTDA.BO's competition here
Transchem Limited (BSE: TRANSCHEM.BO)
TMTIND-B1.BO vs TRANSCHEM.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, TRANSCHEM.BO has a market cap of 4.8B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while TRANSCHEM.BO trades at ₹393.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas TRANSCHEM.BO's P/E ratio is 104.48. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to TRANSCHEM.BO's ROE of +0.08%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to TRANSCHEM.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check TRANSCHEM.BO's competition here
Jenburkt Pharmaceuticals Limited (BSE: JENBURPH.BO)
TMTIND-B1.BO vs JENBURPH.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, JENBURPH.BO has a market cap of 4.3B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while JENBURPH.BO trades at ₹978.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas JENBURPH.BO's P/E ratio is 12.43. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to JENBURPH.BO's ROE of +0.17%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to JENBURPH.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check JENBURPH.BO's competition here
Infinium Pharmachem Ltd. (NSE: INFINIUM.NS)
TMTIND-B1.BO vs INFINIUM.NS Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, INFINIUM.NS has a market cap of 4.1B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while INFINIUM.NS trades at ₹265.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas INFINIUM.NS's P/E ratio is 43.95. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to INFINIUM.NS's ROE of N/A. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to INFINIUM.NS. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check INFINIUM.NS's competition here
Trident Lifeline Limited (BSE: TLL.BO)
TMTIND-B1.BO vs TLL.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, TLL.BO has a market cap of 3.8B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while TLL.BO trades at ₹315.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas TLL.BO's P/E ratio is 19.29. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to TLL.BO's ROE of +0.23%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to TLL.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check TLL.BO's competition here
Ambalal Sarabhai Enterprises Limited (BSE: AMBALALSA.BO)
TMTIND-B1.BO vs AMBALALSA.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, AMBALALSA.BO has a market cap of 3.1B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while AMBALALSA.BO trades at ₹40.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas AMBALALSA.BO's P/E ratio is 17.19. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to AMBALALSA.BO's ROE of +0.09%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to AMBALALSA.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check AMBALALSA.BO's competition here
BDH Industries Limited (BSE: BDH.BO)
TMTIND-B1.BO vs BDH.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, BDH.BO has a market cap of 2.9B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while BDH.BO trades at ₹503.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas BDH.BO's P/E ratio is 34.22. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to BDH.BO's ROE of +0.16%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to BDH.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check BDH.BO's competition here
Zenotech Laboratories Limited (BSE: ZENOTECH.BO)
TMTIND-B1.BO vs ZENOTECH.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, ZENOTECH.BO has a market cap of 2.7B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while ZENOTECH.BO trades at ₹44.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas ZENOTECH.BO's P/E ratio is 142.71. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to ZENOTECH.BO's ROE of -0.03%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to ZENOTECH.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check ZENOTECH.BO's competition here
Gennex Laboratories Limited (BSE: GENNEX.BO)
TMTIND-B1.BO vs GENNEX.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, GENNEX.BO has a market cap of 2.5B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while GENNEX.BO trades at ₹10.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas GENNEX.BO's P/E ratio is 12.68. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to GENNEX.BO's ROE of +0.08%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to GENNEX.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check GENNEX.BO's competition here
Kerala Ayurveda Limited (BSE: KERALAYUR.BO)
TMTIND-B1.BO vs KERALAYUR.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, KERALAYUR.BO has a market cap of 2.2B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while KERALAYUR.BO trades at ₹170.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas KERALAYUR.BO's P/E ratio is -18.71. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to KERALAYUR.BO's ROE of -2.76%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to KERALAYUR.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check KERALAYUR.BO's competition here
Sanjivani Paranteral Limited. (BSE: SANJIVIN.BO)
TMTIND-B1.BO vs SANJIVIN.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, SANJIVIN.BO has a market cap of 2.2B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while SANJIVIN.BO trades at ₹179.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas SANJIVIN.BO's P/E ratio is 47.82. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to SANJIVIN.BO's ROE of +0.17%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to SANJIVIN.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check SANJIVIN.BO's competition here
Coral Laboratories Limited (BSE: CORALAB.BO)
TMTIND-B1.BO vs CORALAB.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, CORALAB.BO has a market cap of 2B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while CORALAB.BO trades at ₹570.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas CORALAB.BO's P/E ratio is 15.06. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to CORALAB.BO's ROE of +0.09%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to CORALAB.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check CORALAB.BO's competition here
Oxygenta Pharmaceutical Ltd. (BSE: OXYGENTAPH.BO)
TMTIND-B1.BO vs OXYGENTAPH.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, OXYGENTAPH.BO has a market cap of 2B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while OXYGENTAPH.BO trades at ₹53.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas OXYGENTAPH.BO's P/E ratio is -53.09. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to OXYGENTAPH.BO's ROE of +0.39%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to OXYGENTAPH.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check OXYGENTAPH.BO's competition here
Smruthi Organics Limited (BSE: SMRUTHIORG.BO)
TMTIND-B1.BO vs SMRUTHIORG.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, SMRUTHIORG.BO has a market cap of 1.8B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while SMRUTHIORG.BO trades at ₹158.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas SMRUTHIORG.BO's P/E ratio is 24.47. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to SMRUTHIORG.BO's ROE of +0.10%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to SMRUTHIORG.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check SMRUTHIORG.BO's competition here
Auro Laboratories Limited (BSE: AUROLAB.BO)
TMTIND-B1.BO vs AUROLAB.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, AUROLAB.BO has a market cap of 1.6B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while AUROLAB.BO trades at ₹249.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas AUROLAB.BO's P/E ratio is 41.44. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to AUROLAB.BO's ROE of +0.10%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to AUROLAB.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check AUROLAB.BO's competition here
Panchsheel Organics Limited (BSE: PANCHSHEEL.BO)
TMTIND-B1.BO vs PANCHSHEEL.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, PANCHSHEEL.BO has a market cap of 1.5B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while PANCHSHEEL.BO trades at ₹111.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas PANCHSHEEL.BO's P/E ratio is 13.57. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to PANCHSHEEL.BO's ROE of +0.07%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to PANCHSHEEL.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check PANCHSHEEL.BO's competition here
Syschem (India) Limited (BSE: SYSCHEM.BO)
TMTIND-B1.BO vs SYSCHEM.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, SYSCHEM.BO has a market cap of 1.5B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while SYSCHEM.BO trades at ₹29.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas SYSCHEM.BO's P/E ratio is 496.00. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to SYSCHEM.BO's ROE of +0.06%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to SYSCHEM.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check SYSCHEM.BO's competition here
Parnax Lab Limited (BSE: PARNAXLAB.BO)
TMTIND-B1.BO vs PARNAXLAB.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, PARNAXLAB.BO has a market cap of 1.4B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while PARNAXLAB.BO trades at ₹125.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas PARNAXLAB.BO's P/E ratio is 66.30. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to PARNAXLAB.BO's ROE of +0.10%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to PARNAXLAB.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check PARNAXLAB.BO's competition here
Kimia Biosciences Ltd. (BSE: KIMIABL.BO)
TMTIND-B1.BO vs KIMIABL.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, KIMIABL.BO has a market cap of 1.4B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while KIMIABL.BO trades at ₹29.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas KIMIABL.BO's P/E ratio is 33.12. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to KIMIABL.BO's ROE of +0.55%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to KIMIABL.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check KIMIABL.BO's competition here
Lactose (India) Limited (BSE: LACTOSE.BO)
TMTIND-B1.BO vs LACTOSE.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, LACTOSE.BO has a market cap of 1.3B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while LACTOSE.BO trades at ₹101.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas LACTOSE.BO's P/E ratio is 21.12. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to LACTOSE.BO's ROE of +0.11%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to LACTOSE.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check LACTOSE.BO's competition here
Quest Laboratories Ltd. (NSE: QUESTLAB.NS)
TMTIND-B1.BO vs QUESTLAB.NS Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, QUESTLAB.NS has a market cap of 1.2B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while QUESTLAB.NS trades at ₹74.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas QUESTLAB.NS's P/E ratio is 8.97. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to QUESTLAB.NS's ROE of N/A. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to QUESTLAB.NS. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check QUESTLAB.NS's competition here
Tyche Industries Limited (BSE: TYCHE.BO)
TMTIND-B1.BO vs TYCHE.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, TYCHE.BO has a market cap of 1.1B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while TYCHE.BO trades at ₹110.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas TYCHE.BO's P/E ratio is 11.25. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to TYCHE.BO's ROE of +0.03%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to TYCHE.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check TYCHE.BO's competition here
Godavari Drugs Limited (BSE: GODAVARI.BO)
TMTIND-B1.BO vs GODAVARI.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, GODAVARI.BO has a market cap of 1.1B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while GODAVARI.BO trades at ₹112.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas GODAVARI.BO's P/E ratio is 25.80. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to GODAVARI.BO's ROE of +0.07%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to GODAVARI.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check GODAVARI.BO's competition here
Makers Laboratories Limited (BSE: MAKERSL.BO)
TMTIND-B1.BO vs MAKERSL.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, MAKERSL.BO has a market cap of 1.1B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while MAKERSL.BO trades at ₹185.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas MAKERSL.BO's P/E ratio is -147.03. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to MAKERSL.BO's ROE of +0.04%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to MAKERSL.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check MAKERSL.BO's competition here
Pharmaids Pharmaceuticals Limited (BSE: PHARMAID.BO)
TMTIND-B1.BO vs PHARMAID.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, PHARMAID.BO has a market cap of 1B. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while PHARMAID.BO trades at ₹29.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas PHARMAID.BO's P/E ratio is -39.05. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to PHARMAID.BO's ROE of -0.09%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to PHARMAID.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check PHARMAID.BO's competition here
Sotac Pharmaceuticals Ltd. (NSE: SOTAC.NS)
TMTIND-B1.BO vs SOTAC.NS Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, SOTAC.NS has a market cap of 995.1M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while SOTAC.NS trades at ₹90.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas SOTAC.NS's P/E ratio is 11.63. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to SOTAC.NS's ROE of N/A. Regarding short-term risk, TMTIND-B1.BO is similarly volatile compared to SOTAC.NS. This indicates similar risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check SOTAC.NS's competition here
Vaishali Pharma Limited (NSE: VAISHALI.NS)
TMTIND-B1.BO vs VAISHALI.NS Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, VAISHALI.NS has a market cap of 942.2M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while VAISHALI.NS trades at ₹8.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas VAISHALI.NS's P/E ratio is -3.26. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to VAISHALI.NS's ROE of +0.06%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to VAISHALI.NS. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check VAISHALI.NS's competition here
Mercury Laboratories Limited (BSE: MERCURYLAB.BO)
TMTIND-B1.BO vs MERCURYLAB.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, MERCURYLAB.BO has a market cap of 936M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while MERCURYLAB.BO trades at ₹780.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas MERCURYLAB.BO's P/E ratio is 25.62. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to MERCURYLAB.BO's ROE of +0.07%. Regarding short-term risk, TMTIND-B1.BO is similarly volatile compared to MERCURYLAB.BO. This indicates similar risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check MERCURYLAB.BO's competition here
Denis Chem Lab Limited (BSE: DENISCHEM.BO)
TMTIND-B1.BO vs DENISCHEM.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, DENISCHEM.BO has a market cap of 912.8M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while DENISCHEM.BO trades at ₹65.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas DENISCHEM.BO's P/E ratio is 10.85. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to DENISCHEM.BO's ROE of +0.09%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to DENISCHEM.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check DENISCHEM.BO's competition here
Concord Drugs Limited (BSE: CONCORD.BO)
TMTIND-B1.BO vs CONCORD.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, CONCORD.BO has a market cap of 836.2M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while CONCORD.BO trades at ₹75.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas CONCORD.BO's P/E ratio is 79.26. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to CONCORD.BO's ROE of +0.05%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to CONCORD.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check CONCORD.BO's competition here
Vilin Bio Med Ltd. (NSE: VILINBIO.NS)
TMTIND-B1.BO vs VILINBIO.NS Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, VILINBIO.NS has a market cap of 809.1M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while VILINBIO.NS trades at ₹58.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas VILINBIO.NS's P/E ratio is 362.50. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to VILINBIO.NS's ROE of N/A. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to VILINBIO.NS. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check VILINBIO.NS's competition here
Sunil Healthcare Ltd. (BSE: SUNLOC.BO)
TMTIND-B1.BO vs SUNLOC.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, SUNLOC.BO has a market cap of 755.2M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while SUNLOC.BO trades at ₹73.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas SUNLOC.BO's P/E ratio is 18.83. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to SUNLOC.BO's ROE of +0.05%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to SUNLOC.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check SUNLOC.BO's competition here
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS)
TMTIND-B1.BO vs ZENITHDRUG.NS Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, ZENITHDRUG.NS has a market cap of 741.7M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while ZENITHDRUG.NS trades at ₹43.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas ZENITHDRUG.NS's P/E ratio is 18.80. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to ZENITHDRUG.NS's ROE of N/A. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to ZENITHDRUG.NS. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check ZENITHDRUG.NS's competition here
Source Natural Foods & Herbal Supplements Ltd. (BSE: SOURCENTRL.BO)
TMTIND-B1.BO vs SOURCENTRL.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, SOURCENTRL.BO has a market cap of 736.7M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while SOURCENTRL.BO trades at ₹114.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas SOURCENTRL.BO's P/E ratio is 21.68. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to SOURCENTRL.BO's ROE of +0.14%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to SOURCENTRL.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check SOURCENTRL.BO's competition here
Bharat Immunologicals & Biologicals Corporation Limited (BSE: BIBCL.BO)
TMTIND-B1.BO vs BIBCL.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, BIBCL.BO has a market cap of 611.4M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while BIBCL.BO trades at ₹14.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas BIBCL.BO's P/E ratio is -4.00. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to BIBCL.BO's ROE of -0.17%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to BIBCL.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check BIBCL.BO's competition here
Phaarmasia Limited (BSE: PHRMASI.BO)
TMTIND-B1.BO vs PHRMASI.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, PHRMASI.BO has a market cap of 600.8M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while PHRMASI.BO trades at ₹88.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas PHRMASI.BO's P/E ratio is 3.42. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to PHRMASI.BO's ROE of +1.35%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to PHRMASI.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check PHRMASI.BO's competition here
Parmax Pharma Limited (BSE: PARMAX.BO)
TMTIND-B1.BO vs PARMAX.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, PARMAX.BO has a market cap of 505.3M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while PARMAX.BO trades at ₹135.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas PARMAX.BO's P/E ratio is -12.14. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to PARMAX.BO's ROE of +0.28%. Regarding short-term risk, TMTIND-B1.BO is similarly volatile compared to PARMAX.BO. This indicates similar risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check PARMAX.BO's competition here
Vasundhara Rasayans Limited (BSE: VRL.BO)
TMTIND-B1.BO vs VRL.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, VRL.BO has a market cap of 499.5M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while VRL.BO trades at ₹157.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas VRL.BO's P/E ratio is 8.62. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to VRL.BO's ROE of +0.15%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to VRL.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check VRL.BO's competition here
ANG Lifesciences India Limited (BSE: ANG.BO)
TMTIND-B1.BO vs ANG.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, ANG.BO has a market cap of 495.8M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while ANG.BO trades at ₹37.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas ANG.BO's P/E ratio is -4.46. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to ANG.BO's ROE of -0.22%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to ANG.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check ANG.BO's competition here
Shelter Pharma Limited (BSE: SHELTER.BO)
TMTIND-B1.BO vs SHELTER.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, SHELTER.BO has a market cap of 416.4M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while SHELTER.BO trades at ₹36.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas SHELTER.BO's P/E ratio is 6.98. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to SHELTER.BO's ROE of +0.15%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to SHELTER.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check SHELTER.BO's competition here
Panjon Ltd. (BSE: PANJON.BO)
TMTIND-B1.BO vs PANJON.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, PANJON.BO has a market cap of 377.3M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while PANJON.BO trades at ₹21.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas PANJON.BO's P/E ratio is 549.50. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to PANJON.BO's ROE of +0.04%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to PANJON.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check PANJON.BO's competition here
Vista Pharmaceuticals Limited (BSE: VISTAPH.BO)
TMTIND-B1.BO vs VISTAPH.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, VISTAPH.BO has a market cap of 361.9M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while VISTAPH.BO trades at ₹5.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas VISTAPH.BO's P/E ratio is -3.05. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to VISTAPH.BO's ROE of -0.27%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to VISTAPH.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check VISTAPH.BO's competition here
Sandu Pharmaceuticals Limited (BSE: SANDUPHQ.BO)
TMTIND-B1.BO vs SANDUPHQ.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, SANDUPHQ.BO has a market cap of 357.5M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while SANDUPHQ.BO trades at ₹37.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas SANDUPHQ.BO's P/E ratio is 20.33. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to SANDUPHQ.BO's ROE of +0.04%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to SANDUPHQ.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check SANDUPHQ.BO's competition here
Roopa Industries Limited (BSE: ROOPAIND.BO)
TMTIND-B1.BO vs ROOPAIND.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, ROOPAIND.BO has a market cap of 346.9M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while ROOPAIND.BO trades at ₹44.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas ROOPAIND.BO's P/E ratio is 339.31. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to ROOPAIND.BO's ROE of +0.01%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to ROOPAIND.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check ROOPAIND.BO's competition here
Medi-Caps Limited (BSE: MEDICAPQ.BO)
TMTIND-B1.BO vs MEDICAPQ.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, MEDICAPQ.BO has a market cap of 321.8M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while MEDICAPQ.BO trades at ₹25.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas MEDICAPQ.BO's P/E ratio is 38.52. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to MEDICAPQ.BO's ROE of -0.02%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to MEDICAPQ.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check MEDICAPQ.BO's competition here
Bacil Pharma Limited (BSE: BACPHAR.BO)
TMTIND-B1.BO vs BACPHAR.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, BACPHAR.BO has a market cap of 307.7M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while BACPHAR.BO trades at ₹21.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas BACPHAR.BO's P/E ratio is 71.81. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to BACPHAR.BO's ROE of +0.03%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to BACPHAR.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check BACPHAR.BO's competition here
Gujarat Terce Laboratories Limited (BSE: GUJTERC.BO)
TMTIND-B1.BO vs GUJTERC.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, GUJTERC.BO has a market cap of 286.6M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while GUJTERC.BO trades at ₹36.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas GUJTERC.BO's P/E ratio is 40.55. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to GUJTERC.BO's ROE of +0.26%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to GUJTERC.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check GUJTERC.BO's competition here
Deccan Health Care Ltd (BSE: DECCAN.BO)
TMTIND-B1.BO vs DECCAN.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, DECCAN.BO has a market cap of 286.1M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while DECCAN.BO trades at ₹11.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas DECCAN.BO's P/E ratio is 11.33. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to DECCAN.BO's ROE of +0.02%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to DECCAN.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check DECCAN.BO's competition here
Trimurthi Limited (BSE: TRIMURTHI.BO)
TMTIND-B1.BO vs TRIMURTHI.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, TRIMURTHI.BO has a market cap of 264.8M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while TRIMURTHI.BO trades at ₹26.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas TRIMURTHI.BO's P/E ratio is 102.35. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to TRIMURTHI.BO's ROE of +0.02%. Regarding short-term risk, TMTIND-B1.BO is similarly volatile compared to TRIMURTHI.BO. This indicates similar risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check TRIMURTHI.BO's competition here
Medicamen Organics Ltd (NSE: MEDIORG.NS)
TMTIND-B1.BO vs MEDIORG.NS Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, MEDIORG.NS has a market cap of 263.4M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while MEDIORG.NS trades at ₹21.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas MEDIORG.NS's P/E ratio is -6.35. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to MEDIORG.NS's ROE of N/A. Regarding short-term risk, TMTIND-B1.BO is similarly volatile compared to MEDIORG.NS. This indicates similar risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check MEDIORG.NS's competition here
Welcure Drugs & Pharmaceuticals Limited (BSE: WELCURE.BO)
TMTIND-B1.BO vs WELCURE.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, WELCURE.BO has a market cap of 259.5M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while WELCURE.BO trades at ₹0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas WELCURE.BO's P/E ratio is -10.43. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to WELCURE.BO's ROE of -0.34%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to WELCURE.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check WELCURE.BO's competition here
Ishita Drugs and Industries Limited (BSE: ISHITADR.BO)
TMTIND-B1.BO vs ISHITADR.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, ISHITADR.BO has a market cap of 212.3M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while ISHITADR.BO trades at ₹71.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas ISHITADR.BO's P/E ratio is 178.12. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to ISHITADR.BO's ROE of +0.06%. Regarding short-term risk, TMTIND-B1.BO is similarly volatile compared to ISHITADR.BO. This indicates similar risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check ISHITADR.BO's competition here
Chemo Pharma Laboratories Limited (BSE: CHEMOPH.BO)
TMTIND-B1.BO vs CHEMOPH.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, CHEMOPH.BO has a market cap of 196.3M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while CHEMOPH.BO trades at ₹130.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas CHEMOPH.BO's P/E ratio is -1.61. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to CHEMOPH.BO's ROE of -0.92%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to CHEMOPH.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check CHEMOPH.BO's competition here
Zenlabs Ethica Limited (BSE: ZENLABS.BO)
TMTIND-B1.BO vs ZENLABS.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, ZENLABS.BO has a market cap of 185.2M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while ZENLABS.BO trades at ₹28.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas ZENLABS.BO's P/E ratio is -9.58. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to ZENLABS.BO's ROE of -0.27%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to ZENLABS.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check ZENLABS.BO's competition here
Norris Medicines Limited (BSE: NORRIS.BO)
TMTIND-B1.BO vs NORRIS.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, NORRIS.BO has a market cap of 182.4M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while NORRIS.BO trades at ₹18.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas NORRIS.BO's P/E ratio is N/A. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to NORRIS.BO's ROE of +0.02%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to NORRIS.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check NORRIS.BO's competition here
Colinz Laboratories Limited (BSE: COLINZ.BO)
TMTIND-B1.BO vs COLINZ.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, COLINZ.BO has a market cap of 179.5M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while COLINZ.BO trades at ₹71.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas COLINZ.BO's P/E ratio is 169.67. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to COLINZ.BO's ROE of +0.28%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to COLINZ.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check COLINZ.BO's competition here
Sunrest Lifescience Ltd. (NSE: SUNREST.NS)
TMTIND-B1.BO vs SUNREST.NS Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, SUNREST.NS has a market cap of 160.3M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while SUNREST.NS trades at ₹37.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas SUNREST.NS's P/E ratio is 8.00. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to SUNREST.NS's ROE of N/A. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to SUNREST.NS. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check SUNREST.NS's competition here
Shamrock Industrial Co. Ltd. (BSE: SHAMROIN.BO)
TMTIND-B1.BO vs SHAMROIN.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, SHAMROIN.BO has a market cap of 147.9M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while SHAMROIN.BO trades at ₹27.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas SHAMROIN.BO's P/E ratio is -296.45. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to SHAMROIN.BO's ROE of -0.98%. Regarding short-term risk, TMTIND-B1.BO is similarly volatile compared to SHAMROIN.BO. This indicates similar risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check SHAMROIN.BO's competition here
Emmessar Biotech & Nutrition Limited (BSE: EMMESSA.BO)
TMTIND-B1.BO vs EMMESSA.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, EMMESSA.BO has a market cap of 120.2M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while EMMESSA.BO trades at ₹24.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas EMMESSA.BO's P/E ratio is 29.70. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to EMMESSA.BO's ROE of +0.05%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to EMMESSA.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check EMMESSA.BO's competition here
Beryl Drugs Limited (BSE: BERLDRG.BO)
TMTIND-B1.BO vs BERLDRG.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, BERLDRG.BO has a market cap of 120.1M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while BERLDRG.BO trades at ₹23.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas BERLDRG.BO's P/E ratio is 38.58. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to BERLDRG.BO's ROE of +0.07%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to BERLDRG.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check BERLDRG.BO's competition here
Kobo Biotech Ltd. (BSE: KOBO.BO)
TMTIND-B1.BO vs KOBO.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, KOBO.BO has a market cap of 102.2M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while KOBO.BO trades at ₹4.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas KOBO.BO's P/E ratio is -8.30. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to KOBO.BO's ROE of +0.04%. Regarding short-term risk, TMTIND-B1.BO is similarly volatile compared to KOBO.BO. This indicates similar risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check KOBO.BO's competition here
Adline Chem Lab Ltd. (BSE: ADLINE.BO)
TMTIND-B1.BO vs ADLINE.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, ADLINE.BO has a market cap of 76.1M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while ADLINE.BO trades at ₹13.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas ADLINE.BO's P/E ratio is N/A. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to ADLINE.BO's ROE of N/A. Regarding short-term risk, TMTIND-B1.BO is similarly volatile compared to ADLINE.BO. This indicates similar risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check ADLINE.BO's competition here
Ganga Pharmaceuticals Limited (BSE: GANGAPHARM.BO)
TMTIND-B1.BO vs GANGAPHARM.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, GANGAPHARM.BO has a market cap of 73.9M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while GANGAPHARM.BO trades at ₹12.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas GANGAPHARM.BO's P/E ratio is 113.64. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to GANGAPHARM.BO's ROE of +0.01%. Regarding short-term risk, TMTIND-B1.BO is similarly volatile compared to GANGAPHARM.BO. This indicates similar risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check GANGAPHARM.BO's competition here
Hindustan Bio Sciences Limited (BSE: HINDBIO.BO)
TMTIND-B1.BO vs HINDBIO.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, HINDBIO.BO has a market cap of 73.4M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while HINDBIO.BO trades at ₹7.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas HINDBIO.BO's P/E ratio is 48.57. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to HINDBIO.BO's ROE of -0.24%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to HINDBIO.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check HINDBIO.BO's competition here
Trinity League India Limited (BSE: TRINITYLEA.BO)
TMTIND-B1.BO vs TRINITYLEA.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, TRINITYLEA.BO has a market cap of 71M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while TRINITYLEA.BO trades at ₹8.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas TRINITYLEA.BO's P/E ratio is -44.85. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to TRINITYLEA.BO's ROE of -0.05%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to TRINITYLEA.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check TRINITYLEA.BO's competition here
Vivanza Biosciences Limited (BSE: VIVANZA.BO)
TMTIND-B1.BO vs VIVANZA.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, VIVANZA.BO has a market cap of 70.4M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while VIVANZA.BO trades at ₹1.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas VIVANZA.BO's P/E ratio is -181.44. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to VIVANZA.BO's ROE of +0.10%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to VIVANZA.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check VIVANZA.BO's competition here
Tiaan Consumer Ltd. (BSE: TIAANC.BO)
TMTIND-B1.BO vs TIAANC.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, TIAANC.BO has a market cap of 64.5M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while TIAANC.BO trades at ₹6.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas TIAANC.BO's P/E ratio is -48.31. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to TIAANC.BO's ROE of -0.01%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to TIAANC.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check TIAANC.BO's competition here
Decipher Labs Ltd. (BSE: DECIPHER.BO)
TMTIND-B1.BO vs DECIPHER.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, DECIPHER.BO has a market cap of 55.6M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while DECIPHER.BO trades at ₹5.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas DECIPHER.BO's P/E ratio is -0.69. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to DECIPHER.BO's ROE of -0.09%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to DECIPHER.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check DECIPHER.BO's competition here
Fabino Enterprises Ltd (BSE: FABINO.BO)
TMTIND-B1.BO vs FABINO.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, FABINO.BO has a market cap of 42.7M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while FABINO.BO trades at ₹20.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas FABINO.BO's P/E ratio is -7.64. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to FABINO.BO's ROE of +0.01%. Regarding short-term risk, TMTIND-B1.BO is similarly volatile compared to FABINO.BO. This indicates similar risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check FABINO.BO's competition here
Patidar Buildcon Limited (BSE: PATIDAR.BO)
TMTIND-B1.BO vs PATIDAR.BO Comparison September 2026
TMT (India) Ltd. (BSE: TMTIND-B1.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMTIND-B1.BO stands at 43.9M. In comparison, PATIDAR.BO has a market cap of 30.1M. Regarding current trading prices, TMTIND-B1.BO is priced at ₹8.87 on the BSE, while PATIDAR.BO trades at ₹5.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMTIND-B1.BO currently has a P/E ratio of -49.28, whereas PATIDAR.BO's P/E ratio is -12.72. In terms of profitability, TMTIND-B1.BO's ROE is N/A, compared to PATIDAR.BO's ROE of -0.03%. Regarding short-term risk, TMTIND-B1.BO is less volatile compared to PATIDAR.BO. This indicates lower risk in terms of short-term price fluctuations for TMTIND-B1.BO.Check PATIDAR.BO's competition here